Anthera Pharmaceuticals Inc
OTC:ANTH
Anthera Pharmaceuticals Inc
Operating Expenses
Anthera Pharmaceuticals Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anthera Pharmaceuticals Inc
OTC:ANTH
|
Operating Expenses
-$36.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$22.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$11.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$14.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$5.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$8.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Anthera Pharmaceuticals Inc
Glance View
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
See Also
What is Anthera Pharmaceuticals Inc's Operating Expenses?
Operating Expenses
-36.8m
USD
Based on the financial report for Mar 31, 2018, Anthera Pharmaceuticals Inc's Operating Expenses amounts to -36.8m USD.
What is Anthera Pharmaceuticals Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
3%
Over the last year, the Operating Expenses growth was 34%. The average annual Operating Expenses growth rates for Anthera Pharmaceuticals Inc have been -9% over the past three years , 3% over the past five years .
